Co Amoxiclav (Comxicla 125) 125/31mg Powder for Suspension 60ml

125/31mg Powder for Suspension

ANTIBACTERIAL

Product Description:

Co-Amoxiclav (Comxicla 125) 125mg/31mg Powder for Suspension is a combination antibiotic that contains two active ingredients: Amoxicillin (125mg) and Clavulanic Acid (31mg). It is provided in a powder form that is reconstituted with water to create an oral suspension. This combination works by inhibiting the growth of bacteria, making it effective in treating a wide range of bacterial infections. The Clavulanic acid component helps prevent certain bacteria from becoming resistant to amoxicillin, enhancing the effectiveness of the antibiotic.

Each 5mL of the prepared suspension contains 125mg of Amoxicillin and 31mg of Clavulanic Acid.

Indications:

Co-Amoxiclav (Comxicla 125) 125mg/31mg Powder for Suspension is indicated for the treatment of various infections caused by susceptible bacteria, including:

1. Respiratory Infections:

   • Acute and chronic bronchitis.

   • Pneumonia.

   • Sinusitis.

   • Pharyngitis and tonsillitis.

2. Urinary Tract Infections:

   • Cystitis.

   • Pyelonephritis.

   • Other lower and upper urinary tract infections.

3. Skin and Soft Tissue Infections:

   • Cellulitis.

   • Abscesses.

   • Infected wounds.

4. Ear Infections:

   • Otitis media (middle ear infection).

5. Gastrointestinal Infections:

   • Intra-abdominal infections, including peritonitis.

6. Dental Infections:

   • Dental abscess.

   • Periodontal infections.

7. Prevention of Infection in Surgical Procedures (e.g., abdominal, orthopedic, and gynecological surgeries).

Dosage and Administration:

Co-Amoxiclav (Comxicla 125) 125mg/31mg Powder for Suspension is typically administered orally and should be taken as directed by the healthcare provider.

General Dosage:

• Adults and Children (over 12 years of age):

  • Typically, the recommended dose is 5mL (125mg/31mg) suspension every 12 hours.

• Children (under 12 years):

  • Dosage is based on the child’s weight and age. A common dosing regimen is 25mg/kg to 45mg/kg of body weight per day, divided into two doses.

  • For mild infections: 5mL suspension twice daily.

  • For more severe infections: 7.5mL to 10mL twice daily.

• Duration of Treatment:

  • The usual course of treatment is 7-14 days, depending on the severity of the infection. Treatment duration should be determined by the healthcare provider.

Side Effects:

Common side effects of Co-Amoxiclav (Comxicla 125) 125mg/31mg Powder for Suspension can include:

1. Gastrointestinal:

   • Nausea, vomiting, or diarrhea.

   • Indigestion or stomach cramps.

   • Oral thrush or other fungal infections.

2. Skin:

   • Rash, hives, or itching.

   • Photosensitivity (increased sensitivity to sunlight).

3. Liver:

   • Liver dysfunction or elevated liver enzymes (usually reversible after stopping treatment).

4. Blood:

   • Low white blood cell count (leukopenia) or low platelet count (thrombocytopenia).

5. Other:

   • Fatigue, headache, or dizziness.

   • Allergic reactions (ranging from mild skin reactions to severe anaphylaxis in rare cases).

Serious Side Effects (Less Common):

• Severe allergic reactions (e.g., anaphylaxis, difficulty breathing, swelling of face or throat).

• Severe gastrointestinal symptoms such as persistent diarrhea, which could indicate a serious condition like Clostridium difficile-associated diarrhea.

• Liver damage: Yellowing of skin or eyes, dark urine, or pain in the upper abdomen.

• Severe skin reactions: Stevens-Johnson Syndrome or toxic epidermal necrolysis (rare but serious conditions).

Contraindications:

Co-Amoxiclav (Comxicla 125) 125mg/31mg Powder for Suspension should be avoided in the following conditions:

1. Hypersensitivity (allergy) to amoxicillin, clavulanic acid, penicillins, or any other component of the formulation.

2. History of jaundice or liver dysfunction caused by previous use of amoxicillin-clavulanate preparations.

3. Severe renal impairment without appropriate dose adjustment.

4. Mononucleosis (infectious mononucleosis) due to the increased risk of developing rashes when treated with amoxicillin.

5. Penicillin allergy: If the patient has had an allergic reaction to penicillin or cephalosporins in the past, caution should be taken, and the drug may be contraindicated.

Precautions:

• Renal Impairment: Dosage may need to be adjusted for patients with kidney problems.

• Liver Disease: Caution is advised for patients with liver dysfunction, and liver function should be monitored during treatment.

• Superinfection: Prolonged use of antibiotics may result in the overgrowth of non-susceptible organisms, including fungi.

• Pregnancy and Lactation: Co-Amoxiclav is generally considered safe during pregnancy and breastfeeding but should only be used when necessary, under the supervision of a healthcare provider.

Overdose:

Symptoms of overdose may include:

• Severe gastrointestinal symptoms (e.g., nausea, vomiting, and diarrhea).

• Crystalluria (formation of crystals in urine), which may cause kidney issues.

Management:

• Symptomatic treatment is recommended. Patients should be hydrated adequately.

• If overdose occurs, contact a healthcare professional immediately for guidance. In some cases, dialysis may be helpful in eliminating the drug from the body.

Conclusion:

Co-Amoxiclav (Comxicla 125) 125mg/31mg Powder for Suspension is an effective antibiotic for treating a variety of bacterial infections. It combines amoxicillin, a broad-spectrum penicillin antibiotic, with clavulanic acid, a beta-lactamase inhibitor, to enhance its effectiveness against resistant bacteria. Like all antibiotics, it should be used with care to avoid misuse and the development of resistance. Always follow the prescribed dosage, and consult a healthcare provider if any unusual symptoms arise.